GlassScriptPhysician profile
Greg R Blair
NPI 1205084332
$4,937.43
in general payments reported to CMS, 2019-2025
32 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $537 · 2021: $292 · 2022: $564 · 2023: $742 · 2024: $951 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,544.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $602.92 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $579.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $552.93 | 2021-2025 | Verquvo, Steglatro, Capvaxive |
| Janssen Pharmaceuticals, INC | $517.13 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $351.84 | 2019-2023 | |
| Novo Nordisk INC | $310.58 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $301.21 | 2019-2020 | |
| Abbvie INC. | $218.32 | 2023-2025 | Viberzi, Linzess |
| Abbott Laboratories | $211.27 | 2019-2024 | Mitraclip |
| Daiichi Sankyo INC. | $204.60 | 2022-2025 | Injectafer |
| Tactile Systems Technology INC | $147.74 | 2025 | Nimbl, Flexitouch Plus |
| United Therapeutics Corporation | $124.65 | 2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.10 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $84.10 | 2022-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Boston Scientific Corporation | $71.48 | 2024-2025 | Watchman Flx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $66.41 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $57.88 | 2020-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $53.03 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $49.14 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $48.41 | 2024 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.50 | 2024-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $33.63 | 2021-2025 | |
| Pfizer INC. | $29.70 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $28.30 | 2023 | Assure Wcd |
| Otsuka America Pharmaceutical, INC. | $24.79 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $21.66 | 2022 | |
| Sumitomo Pharma America, INC. | $19.64 | 2025 | Gemtesa |
| Exact Sciences Corporation | $18.39 | 2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $16.79 | 2023 | Inspire |
| Bardy Diagnostics, INC. | $16.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.39 | 2025 | Glassia |
| Kowa Pharmaceuticals America, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.